Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Delaying generic competition - Corporate payoffs and the future of Plavix

Article Abstract:

Bristol-Myers Squibb and Sanofi-Aventis had agreed to pay its Canadian manufacturer Apotex $40 million not to release Plavix until 2011 in an effort to keep the generic version off the market, but the settlement fell apart and generic clopidogrel was released for sale. This case shows high-stakes arrangements through which pharmaceutical companies delay sales of generics and keep drug prices high.

Author: Shuchman, Miriam
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
Marketing procedures, Contracts & orders received, Contracts & orders let, New England States, Canada, France, Marketing, Contracts, Contract agreement, Company marketing practices, Bristol-Myers Squibb Co., BMY, Apotex Inc., SNY, Sanofi-Aventis S.A., Plavix (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Approving the vagus-nerve stimulator for depression

Article Abstract:

The vagus-nerve stimulator (VNS) is treated as an adjunctive treatment for the control of epilepsy and was approved by the FDA in 2005. However, the effectiveness and safety of the device are debatable as there are frequent side effects, due to the effect of VNS on the laryngeal nerve like hoarseness, coughing, dyspnea, and sometimes, vocal cord paralysis or infection.

Author: Shuchman, Miriam
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2007
Product development, Electromedical and Electrotherapeutic Apparatus Manufacturing, Neurological & Muscle Stimulators, Care and treatment, Usage, Depression, Mental, Depression (Mood disorder), Cyberonics Inc., CYBX, Neurological stimulators

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Drug risk and free speech- Can Congress ban consumer drug ads?

Article Abstract:

The side effects of consumer drugs and laws regarding the advertising of these drugs are discussed.

Author: Shuchman, Miriam
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2007
Legal issues & crime, Government regulation (cont), Government regulation, Advertising, Advertising Activity, Legal/Government Regulation, Laws, regulations and rules, Complications and side effects, Nonprescription drugs

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Pharmaceutical industry
Similar abstracts:
  • Abstracts: Extraosseous calcifying odontogenic cyst: report of case and review of literature. Odontogenic signs and symptoms as predictors of odontogenic infection
  • Abstracts: Changes in abortions and births and the Texas parental notification law. Can Massachusetts lead the way in health care reform?
  • Abstracts: A fulfilling career with many options. Looking towards a changing future. Patient restraint positions in a psychiatric inpatient service
  • Abstracts: Try point incentives for employee reward and recognition. Encourage corporate compliance and disclosure. Clarify your financial picture with staff management tools
  • Abstracts: Making patient nutrition a top priority. Out to battle the bottle. Taking steps to reduce falls
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.